|
20 Jun 2019 |
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
|
|
20 Jun 2019 |
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
|
|
20 Jun 2019 |
ArTara Therapeutics Announces Initiation of New Immunology Pipeline Program with TARA-002, a Toll-Like Receptor 4 Agonist, Targeting Rare Lymphatic Malformations
|
|
20 Jun 2019 |
Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma
|
|
20 Jun 2019 |
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
|
|
20 Jun 2019 |
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial
|
|
20 Jun 2019 |
Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
|
|
19 Jun 2019 |
G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer
|
|
19 Jun 2019 |
CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
|
|
19 Jun 2019 |
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
|
|
19 Jun 2019 |
Denovo Biopharma Receives Global Rights to a Novel Late-Stage Drug for Alzheimer's Disease from Orion Corporation for Development as a Personalized Medicine
|
|
19 Jun 2019 |
Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM™) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream
|
|
19 Jun 2019 |
Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology Association
|
|
19 Jun 2019 |
Rocket Pharmaceuticals Announces Patient Dosing Has Commenced in Phase 1 Clinical Trial of RP-A501, the First Gene Therapy to Treat a Monogenic Heart Failure Syndrome
|
|
19 Jun 2019 |
Triumvira Immunologics Announces Clearance of IND and CTA by U.S. FDA and Health Canada for Its First TAC T-cell Therapeutic Product Candidate, TAC01-CD19
|
|
19 Jun 2019 |
Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
|
|
19 Jun 2019 |
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
|
|
19 Jun 2019 |
Alligator Bioscience Submits Clinical Trial Application for ATOR-1017
|
|
19 Jun 2019 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
|
|
18 Jun 2019 |
PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects
|
